Receptors: Coronary flow and flow reserve

American Journal of Hypertension

Volumn 13, Issue 1 II SUPPL., 2000, Pages

  Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Coronary flow reserve; Hypertension; Hypertensive heart disease; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; COMBINATION CHEMOTHERAPY; CORONARY HEMODYNAMICS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CORONARY ARTERY BLOOD FLOW; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CORONARY CIRCULATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0033964962     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Dzau VJ: Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens 1994;12(suppl 4):3-10.
2. Frohlich ED, Re RN: Pathophysiology of systemic arterial hypertension, in Alexander RW et al (eds): Hurst's the Heart, Arteries and Veins. New York, McGraw-Hill, 1998, pp 1635-1650.
3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B: The heart in hypertension. N Engl J Med 1992;327:998-1008.
4. Frohlich ED: Risk mechanisms in hypertensive heart disease. Hypertension 1999;34(part2):782-789.
5. Vasan RS, Levy D: The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996;156:1789-1796.
6. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J 3rd, Feinleib M, Castelli WP: The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987;75(suppl I):I26-I33.
7. Frohlich ED, Pfeffer MA: The magnitude of the problem electrocardiographic and echocardiographic aspects, in Safar ME, Farod-Tarazi FM (eds): The Heart in Hypertension. The Netherlands, Kluwer Academic Publishers, 1989, pp 169-178.
8. Mitchell GF, Pfeffer JM, Pfeffer MA: The heart and conduit vessels in hypertension. Med Clin N Am 1997; 81:1247-1271.
9. Dunn FG, Oigman W, Sundgaard-Riise K, Messerli FH, Ventura H, Reisin E, Frohlich ED: Racial differences in cardiac adaptation to essential hypertension determined by echocardial indexes. J Am Coll Cardiol 1983; 1:1348-1351.
10. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, Laragh JH: The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986;7: 639-650.
11. Frohlich ED, Messerli FH, Reisin E, Dunn FG: The problem of obesity and hypertension. Hypertension 1983;5:71-78.
12. Kannel WB, Gordon T, Castelli WP, Margolis JR: Electrocardiographic left ventricular hypertrophy and risk for coronary heart disease: the Framingham heart study. Ann Intern Med 1970;72:813-822.
13. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
14. Frohlich ED: The first Irvine H Page lecture. The mosaic of hypertension: past, present, and future. J Hypertens 1988;6(suppl 4):2-11.
15. McLenachan JM, Henderson E, Morris KL, Dargie HJ: Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317: 787-792.
16. Haider AN, Larson MG, Benjamin EJ, Levy D: Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-1459.
17. Ono Y, Ono H, Matsuoka H, Fujimori T, Frohlich ED: Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999;34:609-616.
18. Scheler S, Motz W, Strauer BE: Mechanism of angina pectoris in patients with systemic hypertension and normal epicardial coronary arteries by arteriogram. Am J Cardiol 1994;73:478-482.
19. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041-1050.
20. Abrahams C, Janicki JS, Weber KT: Myocardial hypertrophy in Macaca fascicularis: structural remodeling of the collagen matrix. Lab Invest 1987;56:676-683.
21. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757-765.
22. Brilla CG, Reams GP, Maisch B, Weber KT: Reninangiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J. 1993;14(suppl J):57-61.
23. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-877.
24. Diez J, Laviedes C, Mayer G, Gil MJ, Monreal I: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-1456.
25. Ross MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998;16: 1031-1041.
26. Viard I, Jaillard C, Ouali R, Saez JM: Angiotensin-IIBinduced expression of proto-oncogene (c-fos, jun-B, and c-jun) mRNA in bovine adrenocortical fasciculata cells (BAC) is mediated by AT-1 receptors. FEBS Lett 1992;313:43-46.
27. Sharma HS, van Heugten HA, Goedbloed MA, Verdouw PD, Lamers JM: Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-beta 1 mRNA in neonatal cardiac fibroblasts. Biochem Biophys Res Commun 1994;205:105-112.
28. Blume A, Herdegen T, Unger T: Angiotensin peptides and inducible transcription factors. J Mol Med 1999;77: 339-357.
29. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:H1769-H1774.
30. van Kesteren CA, van Heugten HA, Lamers JM, Saxena PR, Schalekamp MA, Danser AH: Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol 1997;29:2147-2157.
31. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-269.
32. Kaneko K, Susic D, Nunez E, Frohlich ED: Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996;14:645-653.
33. Nunez E, Hosoya K, Susic D, Frohlich ED: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997;29: 519-524.
34. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I, Diez J: Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999;17:107-114.
35. Frohlich ED, Tarazi RC: Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979;44:959-963.
36. Pegram BL, Ishise S, Frohlich ED: Effect of methyldopa, clonidine and hydralazine on cardiac mass and hemodynamics in Wistar-Kyoto and spontaneously hypertensive rats. Cardiovasc Res 1982;16:40-46.
37. Frohlich ED: Hemodynamics and other determinants in development of ventricular hypertension: conflicting factors in regression. Fed Proceed 1983;42:2709-2715.
38. Frohlich ED: Overview of hemodynamic and non-hemodynamic factors associated with LVH. J Mol Cell Cardiol 1989;21:3-10.
39. Aristizabal D, Messerli FH, Frohlich ED: Disparate structural effects of left and right ventricles by angiotensin converting enzyme inhibitors and calcium antagonists. Am J Cardiol 1994;73:483-487.